About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
CHRS - Coherus BioSciences| Previous Close | $18.34 | Open | $18.41 |
| Volume | 115.5K | Market Cap | 1.352B |
| Yield | Last Dividend |
| Coherus BioSciences Reports Second Quart... | 08/06/20 |
| ??? Second Quarter UDENYCA?? Net Sales of $135.7 Million ?????? Net Income of $59.0 Million ?????? Non-GAAP Net Income of $68.3 Million ??? REDWOOD CI... | |
| Coherus BioSciences (CHRS) Earnings Expe... | 04/30/20 |
| Coherus BioSciences (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get pre... | |
| The Daily Biotech Pulse: Pfizer's Eczema... | 03/19/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 18)... | |
| Coherus (CHRS) to Report Q4 Earnings: Wh... | 02/24/20 |
| We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results. | |
| Stock To Watch: Coherus Biosciences (CHR... | 02/10/20 |
| Coherus Biosciences (CHRS), a biosimilar company, which is all set to report its fourth-quarter and full-year 2019 financial results on February 27, h... | |
| Is Coherus BioSciences (CHRS) Stock Outp... | 01/07/20 |
| Is (CHRS) Outperforming Other Medical Stocks This Year? | |
| Has Coherus BioSciences (CHRS) Outpaced ... | 12/19/19 |
| Is (CHRS) Outperforming Other Medical Stocks This Year? | |
| Media Advisory - Innovative Lifesaving P... | 11/27/19 |
| Unique partnership program is a direct response to the ' Truth and Reconciliation' Commission's 'call to action: " to increase the number of Indigenou... | |
| The Daily Biotech Pulse: Obseva Sinks On... | 11/07/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 6) A... | |
| Coherus BioSciences (CHRS) Q3 Earnings a... | 11/06/19 |
| Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 75.00% and 19.35%, respectively, for the quarter ended September 2019. Do the n... | |
| The Daily Biotech Pulse: Enanta Aces Mid... | 09/26/19 |
| The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs S... | |
| Coherus BioSciences (CHRS) Upgraded to B... | 09/10/19 |
| Coherus BioSciences (CHRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (B... | |
| Coherus BioSciences (CHRS) Beats Q2 Earn... | 08/01/19 |
| Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 500.00% and 2.94%, respectively, for the quarter ended June 2019. Do the number... | |
| Amgen bid to stop Neulasta biosimilar fa... | 07/29/19 |
| Amgen Inc on Monday lost a bid to revive a lawsuit it filed seeking to block Coherus BioSciences Inc from selling a biosimilar version of its blockbus... | |
| The Daily Biotech Pulse: Roche's Flu Dru... | 07/03/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 2) A... | |
| The Daily Biotech Pulse: Celyad To Advan... | 07/02/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 1) A... | |
| Coherus BioSciences (CHRS) Upgraded to S... | 06/27/19 |
| Coherus BioSciences (CHRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This... | |
| The Daily Biotech Pulse: ContraVir's Vol... | 06/21/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 20) ... | |
| 3 Gene Therapy Stocks For A Biotech Port... | 05/20/19 |
| No summary available. | |
| Coherus BioSciences, Inc. (CHRS) CEO Den... | 05/09/19 |
| Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM Company Participants David Arrington - VP, IR and Corpora... | |
| Coherus BioSciences, Inc. (CHRS) Q1 2019... | 05/09/19 |
| CHRS earnings call for the period ending March 31, 2019. | |
| Coherus BioSciences (CHRS) Reports Q1 Lo... | 05/09/19 |
| Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 36.96% and 0.73%, respectively, for the quarter ended March 2019. Do the number... | |
| Coherus BioSciences beats by $0.16, beat... | 05/09/19 |
| No summary available. | |
| Coherus down 8% premarket on settlement ... | 05/06/19 |
| No summary available. | |
| The Daily Biotech Pulse: Obseva Reports ... | 05/03/19 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 2) Al... | |
| Moving Average Crossover Alert: Coherus ... | 04/26/19 |
| https://www.investing.com/analysis/moving-average-crossover-alert-coherus-biosciences-200411525 | |
| The Zacks Analyst Blog Highlights: Incyt... | 04/25/19 |
| The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences | |
| Why Sony, AMC Entertainment Holdings, an... | 04/08/19 |
| Guess which of these stocks could see big changes ahead. | |
| Coherus BioSciences misses by $0.06 | 02/28/19 |
| No summary available. | |
| Titan Pharmaceuticals leads healthcare g... | 02/01/19 |
| No summary available. | |
| Buy rating | 08/10/20 |
| Truist Securities maintains Buy rating and raises Price Target from $26.00 to $30.00 | |
| Buy rating | 08/07/20 |
| HC Wainwright & Co. maintains Buy rating and raises Price Target from $30.00 to $33.00 | |
| Hold rating | 07/16/20 |
| B of A Securities initiates coverage with Neutral rating and announces Price Target of $20.00 | |
| Date | 2020-08-06 (AMC) | Est. (EPS/Rev.) | $0.33/ 104.95M |
| Actual (EPS/Rev.) | $0.81/ $135.67 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
